CClinicalTrials.gg
Enrolling by invitationNCT07585838Updated May 14, 2026

Hope-Focused Motivational Interviewing in Cancer Patients

An interventional study of Hope-Focused Motivational Interviewing in Motivational Intervention, Cancer and Hope, sponsored by Saglik Bilimleri Universitesi. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to examine the effects of hope-focused motivational interviewing on levels of hope, self-efficacy, and self-compassion in patients with cancer receiving radiotherapy, using a randomized controlled design.

Read the detailed description

This study is designed as a randomized controlled experimental study with a pretest-posttest and follow-up design. It will be conducted with individuals diagnosed with cancer who are receiving inpatient care in the Radiation Oncology unit of a City Hospital. According to the G*Power analysis, a minimum of 46 participants (intervention = 23, control = 23) will be included in the study. The computer-aided https://www.random.org/integers/ program will be used to assign the intervention and control groups without bias. The intervention group will receive a "Hope-Focused Motivational Interviewing" program consisting of four sessions delivered twice weekly, while the control group will receive routine treatment and care. Data will be collected using the "Information Form," "Herth Hope Index," "Brief Self-Compassion Scale," and "General Self-Efficacy Scale." Measurements will be obtained before and after the intervention. To minimize bias, data will be collected via Google Forms. The first page of the form will include information about the study along with an informed consent statement, and participants will be required to provide their consent before proceeding. Participants who agree to take part in the study will complete the questionnaires within approximately 15-20 minutes.

02

Conditions studied

  • Motivational Intervention
  • Cancer
  • Hope
  • Self-Compassion
  • Self-Efficacy

Browse trials for

Keywords

  • motivational ıntervention
  • cancer
  • hope
  • self-compassion
  • self-efficacy
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 46 is close to the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Saglik Bilimleri Universitesi is the lead sponsor of 430 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Being 18 years of age or older
  • Having a diagnosis of Stage I-III cancer according to the TNM staging system Receiving radiotherapy at the study center (including adjuvant, neoadjuvant, or definitive RT)
  • Being in the first week of the radiotherapy process
  • Being able to read and understand Turkish and communicate at a level sufficient to participate in interviews
  • Agreeing to attend the intervention sessions at scheduled times and providing written informed consent

Exclusion criteria

Exclusion Criteria:

  • Presence of metastatic disease (Stage IV) or recurrent cancer
  • Receiving concurrent chemotherapy during the radiotherapy process
  • Presence of severe psychiatric conditions that may interfere with participation or the safe implementation of the intervention (e.g., psychotic disorders, bipolar disorder in the manic phase, or severe major depression)
  • Presence of moderate to severe cognitive impairment/dementia, significant attention or concentration problems, or neurological conditions that may compromise the reliability of responses
  • Severe hearing or speech impairments or communication difficulties that would prevent participation in interviews or completion of questionnaires (if appropriate support cannot be provided)
  • Participation in another structured psychosocial intervention program (e.g., hope-based, psychoeducational, or psychotherapeutic programs) during the study period
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Experimental

    Participants in the intervention group will receive an individual-based Hope-Focused Motivational Interviewing program consisting of four sessions delivered twice weekly.

    Behavioral: Hope-Focused Motivational Interviewing

  • No intervention
    Control

    Participants in the control group will receive routine care only and will not be exposed to any structured psychosocial intervention during the study period. Data will be collected at the same time points as the intervention group (baseline, post-test, and 1-month follow-up).

Interventions

  • BehavioralHope-Focused Motivational Interviewing

    Participants in the intervention group will receive an individual-based Hope-Focused Motivational Interviewing program consisting of four sessions delivered twice weekly. Each session will last approximately 30-40 minutes. The program includes the following components: (1) exploration of hope and goal setting, (2) enhancement of self-efficacy, (3) development of self-compassion, and (4) coping with barriers and creating a sustainable coping plan. Assessments will be conducted at baseline (pre-test), post-intervention, and at 1-month follow-up.

06

What researchers measure

Primary outcomes

  1. Herth Hope Index

    The scale consists of 12 items and three subscales: (1) temporality and future, (2) positive readiness and expectancy, and (3) interconnectedness with self and others. Items are rated on a 4-point Likert scale ranging from 0 (strongly disagree) to 3 (strongly agree). The "temporality and future" subscale (items 1, 2, 6, and 11) assesses the temporal dimension of hope; the "positive readiness and expectancy" subscale (items 4, 7, 10, and 12) reflects the emotional-behavioral aspects of hope; and the "interconnectedness" subscale (items 3, 5, 8, and 9) measures relational and contextual aspects of hope. Items 3 and 6 are negatively worded and are reverse scored. The total scale score is obtained by summing responses to all items, while subscale scores are calculated by summing the corresponding items. Total scores range from 12 to 48, with higher scores indicating greater levels of hope.

    Time frame: Baseline, immediately after the 2-week intervention, and 1 month post-intervention

Secondary outcomes

  1. Brief Self-Compassion Scale

    The Brief Self-Compassion Scale consists of 12 items rated on a 5-point Likert scale. Items 1, 4, 8, 9, 11, and 12 are reverse scored. The scale comprises two factors: self-compassion and self-criticism (or maladaptive self-compassion). Total scores range from 12 to 60, with higher scores indicating greater levels of self-compassion.

    Time frame: Baseline, immediately after the 2-week intervention, and 1 month post-intervention

  2. General Self-Efficacy Scale

    The General Self-Efficacy Scale consists of 17 items rated on a 5-point Likert scale. Items 2, 4, 5, 6, 7, 10, 11, 12, 14, 16, and 17 are reverse scored. The scale includes three subscales: initiation, persistence, and maintenance effort. Total scores range from 17 to 85, with higher scores indicating higher levels of self-efficacy.

    Time frame: Baseline, immediately after the 2-week intervention, and 1 month post-intervention

07

Study locations

1 site
  • Bartın University
    Bartın, Bartın 74100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585838
Lead sponsor
Saglik Bilimleri Universitesi
Responsible party
Duygu Özer, PhD (Dr, Bartın Unıversity) — Principal investigator
First posted
May 14, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion